HIV in 2025: 'There Is Hope for the Future,' Say Disease Experts
With new treatments and maybe even a vaccine on the horizon, 2025 could be an important year for improving the lives of ...
Times Union1 个月
A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?
Another drugmaker, Viiv Healthcare, also left out most of Latin America when it allowed generics of its HIV prevention shot in about 90 countries. Sold as Apretude, the bi-monthly shots are about ...
来自MSN1 个月
Twice-yearly shot could help end AIDS. But will it get to everyone who needs it?
Another drugmaker, Viiv Healthcare, also left out most of Latin America when it allowed generics of its HIV prevention shot in about 90 countries. Sold as Apretude, the bi-monthly shots are about ...
PBS1 个月
A twice-yearly shot could help end AIDS, but only if it can get to everyone who needs it
Another drugmaker, Viiv Healthcare, also left out most of Latin America when it allowed generics of its HIV prevention shot in about 90 countries. Sold as Apretude, the bi-monthly shots are about ...
Bizcommunity8 天
Vaccines can put an end to HIV – African governments must take the lead in developing them
Global partners have supported Africa’s progress in HIV vaccine research and development. Organisations such as the US ...
STAT1 个月
Pharmalittle: We’re reading about unsupported drug price hikes, an annual HIV prevention ...
Gilead Sciences plans to begin Phase 3 testing soon for a drug it believes could prevent HIV infection with just a single shot every year, STAT tells us. Such a medicine, if proven effective ...